Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study

J Obstet Gynaecol Can. 2005 Apr;27(4):350-9. doi: 10.1016/s1701-2163(16)30462-5.

Abstract

Objective: To document Canadian women's experience with the transdermal contraceptive patch, a method delivering 150 microg norelgestromin and 20 microg ethinyl estradiol daily.

Methods: We conducted an open-label, multicentre, descriptive cohort study of the contraceptive patch over 9 cycles in 392 women requiring contraception. A single treatment cycle consisted of 3 consecutive 7-day patch applications followed by 1 patch-free week. At the final visit, overall satisfaction and preference for the patch was rated and compared with the previously used contraceptive method.

Results: At baseline, 80.9% of participants were either very satisfied or somewhat satisfied with their previous contraceptive method, 89% having used oral contraceptives. At final observation, 60.6% of participants preferred the patch, 9.3% had no preference; and 30% preferred their previous method (n = 376). A total of 279 participants (71.2%) completed 9 cycles of patch use. Of these, 91% were satisfied with the patch and 74.9% preferred the patch to their previous contraceptive (43% strongly preferred and 31.9% preferred); 9% had no preference; and 16.1% preferred their previous method. Of those who preferred the patch, 82.7% preferred it because of its convenience or simplicity. Across all cycles, 88% of participants recorded perfect compliance. The most common adverse event was application site reactions (most of which were mild), experienced by 49% of participants: 33.7%, 16.5%, and 14.7% at cycles 1, 4, and 9, respectively.

Conclusion: Both preference for and satisfaction with the transdermal contraceptive patch were high. Most participants.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase IV
  • Comparative Study
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Adolescent
  • Adult
  • Cohort Studies
  • Condoms
  • Contraceptive Devices, Female
  • Contraceptives, Oral / therapeutic use
  • Contraceptives, Oral, Combined / administration & dosage*
  • Contraceptives, Oral, Combined / adverse effects
  • Drug Combinations
  • Ethinyl Estradiol / administration & dosage*
  • Ethinyl Estradiol / adverse effects
  • Ethisterone / analogs & derivatives
  • Female
  • Humans
  • Intrauterine Devices
  • Middle Aged
  • Norgestrel / analogs & derivatives
  • Oximes
  • Patient Compliance
  • Patient Satisfaction*
  • Safety
  • Spermatocidal Agents / therapeutic use
  • Treatment Outcome

Substances

  • Contraceptives, Oral
  • Contraceptives, Oral, Combined
  • Drug Combinations
  • Oximes
  • Spermatocidal Agents
  • Norgestrel
  • Ethinyl Estradiol
  • Ethisterone
  • norelgestromin